Krystal Biotech (NASDAQ:KRYS) Shares Gap Down – What’s Next?

Krystal Biotech, Inc. (NASDAQ:KRYS)’s stock price gapped down before the market opened on Monday. The stock had previously closed at $332.29, but opened at $314.21. Krystal Biotech shares last traded at $288.5770, with a volume of 126,905 shares traded.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. William Blair raised Krystal Biotech to a “strong-buy” rating in a research report on Wednesday, September 23rd. Zacks Research lowered Krystal Biotech from a “hold” rating to a “strong sell” rating in a research report on Friday, October 23rd. Citigroup reaffirmed a “buy” rating on shares of Krystal Biotech in a research note on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating and set a $361.00 price target on shares of Krystal Biotech in a research note on Thursday, October 15th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a report on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $377.20.

Krystal Biotech Stock Performance

The company’s 50 day moving average price is $337.46 and its 200 day moving average price is $308.68. The company has a market cap of $8.46 billion, a price-to-earnings ratio of 35.91 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The business had revenue of $127.34 million for the quarter, compared to the consensus estimate of $125.77 million. On average, equities research analysts forecast that Krystal Biotech, Inc. will post 7.33 EPS for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, Director Dino Rossi sold 25,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director directly owned 50,000 shares in the company, valued at $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the sale, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This represents a 1.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Krystal Biotech during the second quarter valued at approximately $1,554,113,000. William Blair Investment Management LLC bought a new position in shares of Krystal Biotech in the second quarter valued at approximately $211,909,000. Jupiter Topco LLC acquired a new stake in shares of Krystal Biotech in the second quarter worth $95,387,000. Bank of America Corp DE acquired a new stake in shares of Krystal Biotech in the second quarter worth $95,308,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Krystal Biotech in the second quarter worth $60,809,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.